Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 9;13(6):669–676. doi: 10.3109/15412555.2016.1170111

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The Author(s). Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 3. — Rate of COPD exacerbations of any severity (A) overall (individual studies and pooled analyses)^a and (B) stratified by GOLD group (pooled analysis). ^aExacerbations analyses from the individual ACLIFORM and AUGMENT studies are reported for the ITT-exacerbations populations of the aclidinium monotherapy and placebo arms only (579 and 669 patients, respectively; all patients who received at least one dose of the study medication), as specified in the study protocols and published previously (20,32); pooled analyses include data from the ITT populations (577 and 668 patients, respectively; all patients who received at least one dose of the study medication and had a baseline and ≥1 post-baseline FEV₁ assessment) for consistency with the ACCORD I, ACCORD II and ATTAIN study populations. Percentages are the proportion of all GOLD-classified patients (N = 2,459) in each GOLD group. CI, confidence interval; COPD, chronic obstructive pulmonary disease; GOLD, Global initiative for chronic Obstructive Lung Disease; ITT, intent-to-treat; RR, rate ratio; N, number of patients in aclidinium 400 μg and placebo groups.